AstraZeneca PLC
AZN
Company Profile
Business description
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.
Contact
1 Francis Crick Avenue
Cambridge Biomedical Campus
CambridgeCB2 0AA
GBRT: +44 2037495000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2026
Employees
96,100
Stocks News & Analysis
stocks
Investors overlooking ASX share’s potential
International expansion is a distraction from valuable local business.
stocks
Cerebras sees blockbuster demand, setting stage for US AI IPO frenzy
The chipmaker’s IPO priced at $185, well above its initial range, and opened trading at an eye-popping $350.
stocks
What did Morningstar subscribers buy and sell in April?
How the most traded shares in April stack up against our analysts views.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,788.10 | 30.40 | -0.34% |
| CAC 40 | 7,952.55 | 129.72 | -1.61% |
| DAX 40 | 23,950.57 | 505.69 | -2.07% |
| Dow JONES (US) | 49,526.17 | 537.29 | -1.07% |
| FTSE 100 | 10,195.37 | 177.56 | -1.71% |
| HKSE | 25,962.73 | 426.31 | -1.62% |
| NASDAQ | 26,225.14 | 410.08 | -1.54% |
| Nikkei 225 | 61,120.33 | 288.96 | -0.47% |
| NZX 50 Index | 12,875.24 | 89.77 | -0.69% |
| S&P 500 | 7,408.50 | 92.74 | -1.24% |
| S&P/ASX 200 | 8,552.50 | 25.40 | -0.30% |
| SSE Composite Index | 4,135.39 | 42.53 | -1.02% |